全文获取类型
收费全文 | 894篇 |
免费 | 70篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 105篇 |
妇产科学 | 26篇 |
基础医学 | 107篇 |
口腔科学 | 7篇 |
临床医学 | 83篇 |
内科学 | 163篇 |
皮肤病学 | 20篇 |
神经病学 | 53篇 |
特种医学 | 86篇 |
外科学 | 82篇 |
综合类 | 5篇 |
预防医学 | 67篇 |
眼科学 | 22篇 |
药学 | 56篇 |
肿瘤学 | 71篇 |
出版年
2022年 | 8篇 |
2021年 | 9篇 |
2020年 | 7篇 |
2019年 | 12篇 |
2018年 | 9篇 |
2016年 | 15篇 |
2015年 | 12篇 |
2014年 | 24篇 |
2013年 | 29篇 |
2012年 | 51篇 |
2011年 | 51篇 |
2010年 | 27篇 |
2009年 | 25篇 |
2008年 | 36篇 |
2007年 | 41篇 |
2006年 | 31篇 |
2005年 | 37篇 |
2004年 | 30篇 |
2003年 | 40篇 |
2002年 | 41篇 |
2001年 | 35篇 |
2000年 | 18篇 |
1999年 | 21篇 |
1998年 | 12篇 |
1997年 | 14篇 |
1996年 | 7篇 |
1995年 | 8篇 |
1992年 | 10篇 |
1991年 | 21篇 |
1990年 | 15篇 |
1989年 | 14篇 |
1988年 | 12篇 |
1987年 | 11篇 |
1986年 | 22篇 |
1985年 | 10篇 |
1984年 | 10篇 |
1983年 | 10篇 |
1982年 | 8篇 |
1980年 | 7篇 |
1979年 | 9篇 |
1978年 | 13篇 |
1977年 | 8篇 |
1976年 | 8篇 |
1975年 | 8篇 |
1974年 | 6篇 |
1973年 | 15篇 |
1972年 | 6篇 |
1971年 | 8篇 |
1969年 | 10篇 |
1966年 | 12篇 |
排序方式: 共有964条查询结果,搜索用时 109 毫秒
1.
An analysis of the sensory responses of the acoustic cortex 总被引:1,自引:0,他引:1
2.
This prospective study investigated the effects of standard pharmacotherapy in out-of-hospital ventricular fibrillation (VF) after i.v. or endobronchial (e.b.) administration of epinephrine and lidocaine. METHODS. Only patients presenting with out-of-hospital VF were included in this study, whereby VF of noncardiac origin was excluded. Cardiopulmonary resuscitation (CPR) was performed according to the guidelines of the American Heart Association. Basic life support was initiated by Emergency Medical Service (EMS) technicians. The first step of advanced life support was immediate defibrillation by the EMS physician. Epinephrine was given in doses of 2.5 mg e.b. or 1.0 mg i.v. If indicated, patients received 200-500 mg lidocaine e.b. or 100 mg i.v. The course of CPR was tape-recorded and 2-3 blood samples were taken from each patient for drug monitoring. Plasma levels of epinephrine and lidocaine were measured by high-pressure liquid and gas chromatography, respectively, and then correlated to the course of CPR. RESULTS. Forty-seven patients presented VF on arrival of the EMS physician. Restoration of spontaneous circulation was achieved in 64% (Table 3), and 30% of the patients were discharged from hospital without major neurologic deficits. Immediate defibrillation before initiation of pharmacotherapy produced a success rate of 15.8%, whereas defibrillation after drug therapy was successful in 61.5% of cases. Following e.b. instillation of 2.5 mg epinephrine (Fig. 1), median peak concentrations of epinephrine (40.2, range 4.0-79.8 ng/ml) were reached after 3-4 min and plasma levels greater than or equal to 10 ng/ml were seen for 20 min. After i.v. injection of 1.0 mg epinephrine (Fig. 2) maximum concentrations (71.6, range 4.7-104.2 ng/ml) were measured after 1-2 min and plasma levels decreased below 10 ng/ml after 10 min. Following e.b. instillation of 400-500 mg lidocaine mean lidocaine concentrations within the therapeutic range (2-5 micrograms/ml) were reached after 4-5 min and remained within these limits for 20-30 min. Peak concentrations were obtained after 12 min. Doses of 200-320 mg lidocaine e.b. failed to achieve therapeutic plasma levels (Fig. 3). Regarding the pharmacodynamic aspects of drug therapy, 22.5% of the initial survivors were resuscitated from VF without therapeutic epinephrine, presenting with mean endogenous epinephrine concentrations of 7.1 ng/ml, 51.6% of patients were resuscitated after epinephrine therapy with plasma concentrations greater than 20 ng/ml. In only 1 case could a relationship be demonstrated between the administration of lidocaine and resuscitation success. CONCLUSION. In CPR, the e.b. administration of epinephrine and lidocaine is a reliable alternative to the i.v. injection route of these drugs. Recommended doses are 2.5 mg for epinephrine and 400-500 mg for lidocaine. Resuscitation from VF requires immediate epinephrine therapy if initial defibrillation is not successful. Lidocaine has no effect on resuscitation from VF and therefore should be used specifically for antiarrhythmic therapy after restoration of spontaneous circulation. 相似文献
3.
4.
D. J. Fretland C. P. Anglin M. Bremer P. Isakson D. L. Widomski S. K. Paulson S. H. Docter S. W. Djuric T. D. Penning S. Yu J. P. McKearn 《Inflammation》1995,19(2):193-205
Leukotriene B4 (LTB4) and 12(R)-hydroxyeicosatetraenoic acid [12(R)-HETE] are proinflammatory products of arachidonic acid metabolism that have been implicated as mediators in a number of inflammatory diseases. When injected intradermally into the guinea pig, LTB4 and 12(R)-HETE elicit a dose-dependent migration (chemotaxis) of neutrophils (PMNs) into the injection sites as assessed by the presence of a neutrophil marker enzyme myeloperoxidase. SC-41930 {7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxyl]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid}, a first-generation LTB4 receptor antagonist, inhibited the chemotactic actions of LTB4 when given orally with an ED50 value of 1.7 mg/kg. The second-generation LTB4 receptor antagonist, SC-53228 [(+)-(S)-7-(3-{2-(cyclopropylmethyl)-3-methoxy-4-[(methylamino)carbonyl]phenoxy} propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-propanoic acid], inhibited LTB4-induced chemotaxis when given intragastrically with an ED50 value of 0.07 mg/kg. Furthermore, SC-53228 inhibited 12(R)-HETE-induced granulocyte chemotaxis with an oral ED50 value of 5.8 mg/kg. When dosed orally over a range of 0.03–100 mg/kg, SC-53228 gaveC
max plasma concentrations of 0.015–41.1g/ml. SC-53228 inhibited LTB4-primed membrane depolarization of human neutrophils with an IC50 value of 34 nM. As a potent LTB4 receptor antagonist, SC-53228 may well have application in the medical management of disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease, contact dermatitis, and psoriasis, in which LTB4 and/or 12(R)-HETE are implicated as inflammatory mediators. 相似文献
5.
6.
7.
Model for assessment of proficiency of human immunodeficiency virus type 1 sequencing-based genotypic antiretroviral assays
下载免费PDF全文
![点击此处可从《Journal of clinical microbiology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Huang DD Bremer JW Brambilla DJ Palumbo PE Aldrovandi G Eshleman S Brown C Fiscus S Frenkel L Hamdan H Hart S Kovacs A Krogstad P LaRussa P Sullivan J Weinberg A Zhao YQ;Pediatric ACTG Sequencing Working Group 《Journal of clinical microbiology》2005,43(8):3963-3970
Use of sequencing-based genotyping as a diagnostic assay for human immunodeficiency virus (HIV) antiretroviral resistance is increasing. Periodic evaluation of the proficiency of laboratories performing this assay should be established. It is important to identify components of the assay that influence the generation of reliable sequencing data and that should and can be monitored. A model was developed to determine what parameters were reasonable and feasible for assessing the performance of genotyping assays. Ten laboratories using the genotyping platform, HIV-1 Genotyping System (HGS) v. 1 and software versions 1.1 or 2.0, participated in two rounds of testing. For each round, each group was sent a panel consisting of three clinical samples to sequence in real time. Six months later, seven laboratories using the TRUGENE HIV-1 Genotyping Kit participated in a separate round, working with both panels at the same time. Analysis of the data showed that one main indicator of genotyping proficiency was achievement of > or =98% sequence homology of a sample tested to a group consensus sequence for that sample. A second was concordant identification of codons at sites identified with resistance mutations in the sample, although scoring of these criteria is still undetermined from this study. These criteria are applicable to all sequence-based genotyping platforms and have been used as a baseline for assessing the performance of genotyping for the determination of antiretroviral resistance in our ongoing proficiency program. 相似文献
8.
Effect of errors in the sequence of optical densities from the Roche AMPLICOR HIV-1 MONITOR assay on the validity of assay results
下载免费PDF全文
![点击此处可从《Journal of clinical microbiology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Specifications for the AMPLICOR HIV-1 MONITOR kit indicate that the results are invalid if the optical densities (ODs) from the PCR-amplified sample that are between 0.1 and 2.3 units are out of sequence. However, among 11,904 assays, results were biased only when ODs of 0.2 to 2.0 units were out of sequence, reducing the rate of invalid results from 3.2 to 0.59%. 相似文献
9.
Using a preembedding electron microscopic technique, the binding and internalization of gold labelled mistletoe lectin I (MLI.Au), its 2 A subunits (MLI-A.Au) and of the B subunit (MLI-B.Au) in murine L 1210V leukemia cells was analysed. Furthermore, the endocytosis of a gold marked immunotoxin (MoAb-16-MLI-A.Au), consisting of a monoclonal antibody (MoAb-16) reacting with L 1210V cells and the cytotoxic A subunits (MLI-A) was detected. The cells were incubated with MLI.Au, MLI-A.Au, MLI-B.Au, or MoAb-16-MLI-A.Au at 37 degrees C for 1, 3, 5, 10, 20 or 30 min, respectively. Remarkable differences were found in the endocytotic pathway and internalization kinetics. The endocytosis of MLI, its subunits and of the immunotoxin has been compared to that of the other ligands in various systems. 相似文献
10.
Comparison of the sensitivities of the version 1.5 and version 1.0 ultrasensitive Roche AMPLICOR HIV-1 MONITOR kits at low concentrations of human immunodeficiency virus RNA
下载免费PDF全文
![点击此处可从《Journal of clinical microbiology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Brambilla DJ Jennings C Morack R Granger S Bremer JW 《Journal of clinical microbiology》2004,42(6):2819-2820
The sensitivities of the version 1.5 and 1.0 Roche UltraSensitive AMPLICOR HIV-1 MONITOR tests were compared using panels of coded samples of subtype B human immunodeficiency virus type 1 spiked into plasma at predetermined concentrations. Results indicate that the version 1.5 kit is more sensitive than the version 1.0 kit. 相似文献